Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,143 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02432846 | Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)(MERECA) | completed | Phase 2 | 88 | MendusINDUSTRY | 9 | Aug 22, 2022 | clinicaltrials |
| NCT05440045 | A Clinical Study of 6MW3211 in Patients With Renal Cancer | unknown | Phase 2 | 30 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Aug 17, 2022 |
| clinicaltrials |
| NCT01582009 | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | terminated | Phase 1 / Phase 2 | 26 | Roswell Park Cancer InstituteOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT02781506 | Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma | terminated | Phase 2 | 7 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05485883 | Tislelizumab Plus Lenvatinib in Stage III-IV RCC(TILUR) | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05263609 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 154 | Hoosier Cancer Research NetworkOTHER | 3 | Jul 11, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03029780 | An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma(CheckMate 800) | completed | Phase 2 | 104 | Bristol-Myers SquibbINDUSTRY | 3 | Jun 29, 2022 | clinicaltrials |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | terminated | Phase 2 | 21 | University of WashingtonOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT01157091 | Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer | completed | Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT01664182 | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2022 | clinicaltrials |
| NCT00392821 | Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 78 | SCRI Development Innovations, LLCOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05241561 | Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients(Cabo-POLARIS) | not yet recruiting | Phase 2 | 24 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04150562 | Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | May 17, 2022 | clinicaltrials |
| NCT01354431 | BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 168 | Bristol-Myers SquibbINDUSTRY | 4 | May 12, 2022 | clinicaltrials |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma(RENACOL) | withdrawn | Phase 1 / Phase 2 | 0 | Faron Pharmaceuticals LtdINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT00126672 | RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03334409 | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 5 | Academic and Community Cancer Research UnitedOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT00003656 | Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 26 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT01513187 | Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 53 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | terminated | Phase 2 | 8 | TC BiopharmINDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT05262413 | A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | unknown | Phase 1 / Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | Ajjai Alva, MDOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03177239 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)(UNISoN) | unknown | Phase 2 | 85 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Guru SonpavdeOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT00112840 | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01399918 | Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01566747 | Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | completed | Phase 2 | 43 | Cancer Trials IrelandNETWORK | 2 | Dec 23, 2021 | clinicaltrials |
| NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | completed | Phase 1 / Phase 2 | 28 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT02689167 | Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma(SURF) | unknown | Phase 2 | 226 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT00550277 | LBH589 Treatment for Refractory Clear Cell Renal Carcinoma | completed | Phase 2 | 20 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05124431 | Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma(ALTER-UC-001) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT03013335 | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen(NIVOREN) | completed | Phase 2 | 730 | UNICANCEROTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01392183 | Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT03339219 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | completed | Phase 2 | 35 | TakedaINDUSTRY | 1 | Sep 20, 2021 | clinicaltrials |
| NCT01444807 | Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases | unknown | Phase 2 | 132 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04534998 | Robotic-assisted vs. Open Partial Nephrectomy(ROBOCOP) | unknown | Phase 2 | 50 | Universitätsmedizin MannheimOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT02959554 | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control(NIVOSWITCH) | terminated | Phase 2 | 49 | AIO-Studien-gGmbHOTHER | 2 | Sep 8, 2021 | clinicaltrials |
| NCT02599779 | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients(OZM-065) | completed | Phase 2 | 4 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01896271 | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | completed | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01649180 | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma(PrE0801) | terminated | Phase 2 | 3 | PrECOG, LLC.OTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04995016 | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma(PANDORA) | unknown | Phase 2 | 18 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 22, 2022source: clinicaltrials